💻 Technology · Next Week

Nobel Prize in Physiology or Medicine 2026 awarded to Svetlana Mojsov, Jens Juul Holst, and Daniel J. Drucker for the discovery of biologically active GLP-1 (announced October 5, 2026, confirmed by Nobelprize.org by October 6, 2026)

Miss ✦ AI-generated prediction Published on 28. September 2026 · Predicted for 5. October 2026 · Based on: Speculative

Probability

38%

All three were jointly named 2026 Clarivate Citation Laureates for GLP-1 discovery — a predictor with strong historical Nobel correlation. Holst and Drucker also received the 2026 Breakthrough Prize in Life Sciences. Joel Habener's death (2025/26) reduces the viable laureate group to three, simplifying the award. A GLP-1 Nobel is considered medically 'overdue' (Ozempic revolution). No liquid prediction market found for Nobel Medicine 2026 (no Polymarket or Kalshi contract active as of Sept 28, 2026). Probability honestly calibrated at 38%, as the Medicine Nobel regularly surprises.

Data basis for this prediction

Clarivate Citation Laureates 2026: Mojsov, Holst, Drucker für GLP-1 (Rockefeller University News, Sept. 2026)
Breakthrough Prize Life Sciences 2026: Holst & Drucker (Breakthrough Prize, Sept. 2026)
Lasker Award 2024 an Svetlana Mojsov (Lasker Foundation, Okt. 2024)
Kein Polymarket-/Kalshi-Markt für Nobelpreis Medizin 2026 aktiv (Recherche 28.9.2026)

Verdict: Miss

Der Nobelpreis für Physiologie oder Medizin 2026 ging am 5. Oktober 2026 an Karl Deisseroth (Stanford), Peter Hegemann (Humboldt-Universität Berlin) und Georg Nagel (Universität Würzburg) für ihre Entdeckungen zu lichtgesteuerten Ionenkanälen und der Optogenetik – nicht an Mojsov, Holst und Drucker für GLP-1. Trotz der Clarivate-Citation-Laureates-Auszeichnung und des Breakthrough Prize für Holst/Drucker entschied das Nobelkomitee sich für ein grundlagenwissenschaftliches Neurowissenschaftsthema. Dies illustriert das bekannte Muster: Clarivate-Prädiktoren korrelieren langfristig, aber nicht verlässlich im konkreten Jahr. Quellen: nobelprize.org, statnews.com, nature.com (alle 5. Oktober 2026).

Related Predictions

💻 Technology ✦ AI

Applied Materials Inc. (NASDAQ: AMAT) beats Q4 FY2026 EPS consensus of $4.06 per share — earnings report November 12, 2026 after market close (confirmed by Applied Materials Investor Relations or Bloomberg by November 13, 2026, 10:00 AM ET)

Applied Materials has beaten the EPS consensus in all four of its last reported quarters, with an average earnings surprise of +3.5%. The company's own Q4 guidance is $3.82–$4.22 per share; consensus at $4.06 sits near the midpoint, reflecting classic conservative management framing. Revenue is estimated at $10.30B (+51% YoY) — TSMC and Samsung have not pulled back H2 2026 capex plans. No Polymarket market directly available; a 100% beat streak over 4 quarters with a positive guidance range implies 70–75% probability. Risk: supply chain delays or expanded US export controls on advanced chips could force a Q5 inventory build.

72%

Next Week · Predicted for 12. Nov 2026

💻 Technology ✦ AI

Palantir Technologies Inc. (NYSE: PLTR) closes above $185.00 per share on at least one trading day in November 2026 — confirmed by Nasdaq or Bloomberg by December 1, 2026

PLTR closed at $175.40 on November 4, 2026 (after-hours: $170.88, -2.58%; intraday high: $176.54; 52-week high: $212.94). Palantir clearly beat Q3-FY2026 EPS consensus: total revenue $2.313B, US Commercial revenue +148% YoY to $984M. The $185 threshold is +5.5% above the closing price or +8.3% above after-hours levels. Typical post-earnings 'sell the news' may weigh short-term, but the 52-week high of $212.94 confirms the level is reachable. NVIDIA earnings on November 18, 2026 could serve as a sector-wide catalyst. No direct Polymarket equivalent; own estimate: ~42%.

42%

Next Month · Predicted for 30. Nov 2026

💻 Technology ✦ AI

Cerebras Systems (NASDAQ: CBRS) closes below $100.00 per share on November 10, 2026 (confirmed by Nasdaq or Bloomberg by November 11, 2026)

CBRS trades at $109.18 (October 30, 2026) — already 61% below its all-time high of $279.72. The final and largest lockup expiration is scheduled for November 10, 2026: approximately 19.4 million shares are unlocked (of three tranches of 19.4M each). Prior lockup tranches have consistently weighed on the stock. Insiders have sold ~$394.6M in shares since the May 2026 IPO — zero insider purchases. A Culper Research short-seller report has triggered multiple investigations. A close below $100 requires a ~8.4% decline — plausible given the expected supply pressure on expiration day.

62%

Next Week · Predicted for 10. Nov 2026